Stefaan Van Gool MD. Doctor.
Director Médico de Oncología Traslacional del IOZK
Inmunólogo especializado en tumores cerebrales
Stefan Van Gool MD. PhD, es especialista en hemato-oncología pediátrica centrada en los tumores cerebrales. De 2001 a 2004 fue jefe de investigación clínica en el Fondo de Investigación Científica de Flandes. Entre 2006 y 2016 fue profesor en la Facultad de Medicina de la Universidad Católica de Lovaina. De 2012 a 2015 fue jefe del Laboratorio de Inmunología Pediátrica. Es autor de casi 200 artículos científicos en revistas científicas internacionales.
En reconocimiento a sus logros científicos, recibió los siguientes galardones:
1995 Premio Schweißguth de la Sociedad Internacional de Oncología Pediátrica
1996 Premio Nycomed de la Sociedad Internacional de Oncología Pediátrica
1998 Premio a la investigación sobre el cáncer de la Fundación Rik en Nel Wouters (con Ludwig Van den Hove)
Entre 2005 y 2009, fue coordinador del Grupo Europeo de Expertos en Glioma de Alto Grado
Desde 2008 es miembro del Consejo Superior de Sanidad de Bélgica.
De 2014 a 2017, fue copresidente del grupo de trabajo de tumores cerebrales de la Sociedad Europea de Oncología Pediátrica
En el IOZK, es director médico y responsable de la planificación y aplicación de la inmunoterapia del IOZK. Es persona cualificada (GMP) en la producción de medicamentos.
"Dado que cada tumor es diferente, los mejores resultados se consiguen atacando el conjunto único de células tumorales con las células dendríticas del propio paciente"
Stefaan Van Gool MD. Doctor.
Colección: Contribuciones científicas y publicaciones internacionales de Stefaan Van Gool MD. PhD
Más información sobre este tema:
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
The Complexity of Malignant Glioma Treatment
Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution
Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
The Application of Evidence-Based Medicine in Individualized Medicine
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
Stefaan van Gool es editor de un número especial del Journal of Molecular Sciences
Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
Presentación de un póster en la reunión anual de la Asociación para la Inmunoterapia del Cáncer
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival
Impaired DNA repair in mouse monocytes compared to macrophages and precursors
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
Un análisis de IOZK muestra la buena tolerabilidad de la inmunoterapia con IOZK en el glioma pontino intrínseco difuso (DIPG)
Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
Simposio y formación avanzada en el IOZK: Inmunoterapia en neuro-oncología, vie 06.09.2019
Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy
Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group
Artículo del IOZK sobre ensayos de tratamiento del glioblastoma en la revista especializada: "Austin Oncology Case Report"
Conferencia IOZK: Electrohipertermia modulada en niños con DIPG, conferencia ESHO, Charité Berlin
Conferencia del IOZK sobre los efectos de la inmunoterapia multimodal para el glioma de protuberancia utilizando el método de análisis de biopsia líquida.
Conferencia del IOZK por Stefaan Van Gool: Inmunoterapia IOZK para DIPG Ponsglioma, Conferencia de la Sociedad de Neuro-Oncología, San Francisco
Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival
Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade
Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy
Artículo del IOZK en Austin Oncology Case Reports sobre vacunas contra el cáncer
Artículo sobre Stefaan Van Gool como neurooncólogo pediátrico en el Washington Post
Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease
Immunotherapy in atypical teratoid-rhabdoid tumors: Data from a survey of the HGG-Immuno Group
Publicación de Stefaan Van Gool MD. PhD: Electroporación de células dendríticas con WT1, Survivin y TriMix
Artículo del IOZK en la revista de medicina ortomolecular, número especial: Oncología
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines
Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma
Stefaan Van Gool se traslada de la Universidad de Lovaina al IOZK
Tumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients
Brain Tumor Immunotherapy: What have We Learned so Far?
Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model
Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?
Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells
Wilms‘ tumor gene 1 immunotherapy in pelvic gynecological malignancies
Myeloid-derived suppressor cells in glioma
Dendritic cell-based immunotherapy in ovarian cancer
Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials
Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma
Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours
Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination
Dendritic cell therapy of high-grade gliomas
Vaccine therapy in patients with renal cell carcinoma
Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme
Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells
Dendritic cell vaccination in patients with malignant gliomas: current status and future directions
Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report